Momentum Building: Delcath Systems Spikes on HEPZATO KIT's FDA Nod
- August 15th, 2023
- 185 views
Shares of Delcath Systems, Inc. (Nasdaq: DCTH) surged over 50% following the announcement of FDA approval for HEPZATO KIT (melphalan/Hepatic Delivery System).
This liver-directed therapy is now authorized for adult patients battling metastatic uveal melanoma (mUM), specifically those with unresectable hepatic metastases affecting less than 50% of the liver and limited extrahepatic disease.
This approval addresses a rare and aggressive cancer with high liver involvement, making it a significant advancement in treatment options and the company plans to make the commercial product available in the fourth quarter.
$DCTH was trading at $5.35 in pre-market, reflecting a substantial increase of $2.23 (+71.47%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login